<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00191282</url>
  </required_header>
  <id_info>
    <org_study_id>5509</org_study_id>
    <secondary_id>F3Z-MC-IONM</secondary_id>
    <nct_id>NCT00191282</nct_id>
  </id_info>
  <brief_title>Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes</brief_title>
  <acronym>IONM</acronym>
  <official_title>Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes (HEART2D)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective was to demonstrate a difference between two insulin strategies, one
      targeting postprandial (PP) hyperglycemia and the other targeting fasting and interprandial
      hyperglycemia, on time until the first combined adjudicated cardiovascular (CV) event
      (primary outcome defined as CV death, nonfatal myocardial infarction [MI], nonfatal stroke,
      coronary revascularization, or hospitalized acute coronary syndrome).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the effect of two different treatment strategies on
      CV outcomes in patients with type 2 diabetes while aiming to achieve and maintain HbA1c &lt;7.0%
      in both groups. Only patients who have recently experienced an acute MI will be considered
      for participation in this trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Experienced a Primary Combined Outcome</measure>
    <time_frame>Randomization (Day 0) until first occurrence of primary combined outcome (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)</time_frame>
    <description>The combined study outcomes consisted of cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, hospitalization for acute coronary syndromes (HACS), and coronary revascularization procedures planned after randomization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Death From Any Cause or Any One of the Primary Outcomes</measure>
    <time_frame>Randomization (Day 0) until death from any cause or one of the primary outcomes (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)</time_frame>
    <description>Primary outcomes in this study consisted of: cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for acute coronary syndromes (HACS), and coronary revascularization procedure planned after randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Any One of the Primary Outcomes Adjusted for Indicators of Metabolic Control</measure>
    <time_frame>Randomization (Day 0) until occurrence of primary outcome (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)</time_frame>
    <description>Indicators of metabolic control included glycosylated hemoglobin (HbA1c) and fasting blood glucose concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Primary Outcomes Adjusted for Metabolic Control and Major Cardiovascular (CV) Risk Factors</measure>
    <time_frame>Randomization (Day 0) until occurrence of primary outcome (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)</time_frame>
    <description>Primary outcomes adjusted for major cardiovascular (CV) risk factors (blood pressure, cholesterol [total, high density lipoprotein (HDL), and low density lipoprotein (LDL)], triglycerides, smoking, albuminuria, age, gender, and body mass index (BMI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Death From Any Cause</measure>
    <time_frame>Randomization (Day 0) until death from any cause (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Cardiovascular (CV) Death</measure>
    <time_frame>Randomization (Day 0) until cardiovascular death (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Myocardial Infarction (MI)</measure>
    <time_frame>Randomization (Day 0) until myocardial infarction (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)</time_frame>
    <description>Occurrence of myocardial infarction (MI) (fatal, nonfatal, any).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Stroke</measure>
    <time_frame>Randomization (Day 0) until stroke (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)</time_frame>
    <description>Occurrence of stroke (fatal, nonfatal, any).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Hospitalization for Acute Coronary Syndromes (HACS)</measure>
    <time_frame>Randomization (Day 0) until HACS (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Coronary Revascularization Procedures</measure>
    <time_frame>Randomization (Day 0) until coronary revascularization procedures (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)</time_frame>
    <description>Occurrence of all coronary revascularization procedures (angioplasty or coronary artery by-pass surgery) planned after randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Amputation for Peripheral Vascular Disease Planned After Randomization</measure>
    <time_frame>Randomization (Day 0) until amputation (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Congestive Heart Failure</measure>
    <time_frame>Randomization (Day 0) until congestive heart failure (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)</time_frame>
    <description>Occurrence of congestive heart failure (newly diagnosed after Visit 2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Revascularization Procedure for Peripheral Vascular Disease Planned After Randomization</measure>
    <time_frame>Randomization (Day 0) until revascularization procedure (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Coronary Angiography Planned After Randomization</measure>
    <time_frame>Randomization (Day 0) until coronary angiography (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Self-Reported Hypoglycemia During Month 1</measure>
    <time_frame>Visit 3 (Month 1)</time_frame>
    <description>Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 1</measure>
    <time_frame>Visit 3 (Month 1)</time_frame>
    <description>Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Self-Reported Hypoglycemia During Month 3</measure>
    <time_frame>Visit 4 (Month 3)</time_frame>
    <description>Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 3</measure>
    <time_frame>Visit 4 (Month 3)</time_frame>
    <description>Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Self-Reported Hypoglycemia During Month 6</measure>
    <time_frame>Visit 5 (Month 6)</time_frame>
    <description>Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 6</measure>
    <time_frame>Visit 5 (Month 6)</time_frame>
    <description>Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Self-Reported Hypoglycemia During Month 9</measure>
    <time_frame>Visit 6 (Month 9)</time_frame>
    <description>Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 9</measure>
    <time_frame>Visit 6 (Month 9)</time_frame>
    <description>Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Self-Reported Hypoglycemia During Month 12</measure>
    <time_frame>Visit 7 (Month 12)</time_frame>
    <description>Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 12</measure>
    <time_frame>Visit 7 (Month 12)</time_frame>
    <description>Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Self-Reported Hypoglycemia During Month 18</measure>
    <time_frame>Visit 8 (Month 18)</time_frame>
    <description>Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 18</measure>
    <time_frame>Visit 8 (Month 18)</time_frame>
    <description>Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1116</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Postprandial: Premeal insulin lispro +/- bedtime NPH</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fasting: NPH/insulin glargine or human insulin 30/70</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin lispro</intervention_name>
    <description>Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Humalog</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human insulin isophane suspension (NPH)</intervention_name>
    <description>Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values &gt;8.0%</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glargine</intervention_name>
    <description>Insulin glargine injected subcutaneous (SC) once daily in the evening until patient completes study.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human insulin isophane suspension</intervention_name>
    <description>Patient adjusted dose, twice daily, injected subcutaneous (SC) before morning and evening meals until patient completes study.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human insulin 30/70</intervention_name>
    <description>Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Human insulin 70/30 (in the United States)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are at least 30 years old

          -  Have had type 2 diabetes for at least 3 months prior to Visit 1

          -  Were admitted to the Coronary Care Unit (CCU) within 18 days prior to Visit 1 for an
             acute MI

          -  Are capable and willing to do specified study procedures

          -  Have given informed consent to participate in the study in accordance with local
             regulations

        Exclusion Criteria:

          -  Were on one of the following therapies prior to admission to the CCU for the recent
             MI: a)diet therapy only and have glycosylated hemoglobin (HbA1c) &lt;1.15 times the upper
             limit of normal or b) an intensive basal/bolus insulin regimen

          -  Are using any oral antihyperglycemic medication at the time of Visit 2 and are
             unwilling to stop the use of such medication for the duration of the study

          -  Have substantial myocardial damage, which would significantly outweigh the potential
             benefit of the treatment strategies for diabetes

          -  Have the most severe form of congestive heart failure

          -  Have liver disease so severe that it precludes the patient from following and
             completing the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9am-5pm Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-651-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-651-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-651-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-651-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-651-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-651-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-651-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-651-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-651-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-651-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-651-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-651-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Nitra</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-651-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Maribor</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-651-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Parktown</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-651-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-651-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-651-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Israel</country>
    <country>Lebanon</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Slovenia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <results_reference>
    <citation>Raz I, Wilson PW, Strojek K, Kowalska I, Bozikov V, Gitt AK, Jermendy G, Campaigne BN, Kerr L, Milicevic Z, Jacober SJ. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care. 2009 Mar;32(3):381-6. doi: 10.2337/dc08-1671.</citation>
    <PMID>19246588</PMID>
  </results_reference>
  <results_reference>
    <citation>Milicevic Z, Raz I, Beattie SD, Campaigne BN, Sarwat S, Gromniak E, Kowalska I, Galic E, Tan M, Hanefeld M. Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia. Diabetes Care. 2008 Feb;31 Suppl 2:S155-60. doi: 10.2337/dc08-s240. Review.</citation>
    <PMID>18227478</PMID>
  </results_reference>
  <results_reference>
    <citation>Milicevic Z, Raz I, Strojek K, Skrha J, Tan MH, Wyatt JW, Beattie SD, Robbins DC; HEART2D Study. Hyperglycemia and its effect after acute myocardial infarction on cardiovascular outcomes in patients with Type 2 diabetes mellitus (HEART2D) Study design. J Diabetes Complications. 2005 Mar-Apr;19(2):80-7.</citation>
    <PMID>15745837</PMID>
  </results_reference>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <results_first_submitted>October 17, 2008</results_first_submitted>
  <results_first_submitted_qc>June 19, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 4, 2009</results_first_posted>
  <last_update_submitted>January 18, 2011</last_update_submitted>
  <last_update_submitted_qc>January 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>Eli Lilly</organization>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>MI</keyword>
  <keyword>heart attack</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Isophane insulin, beef</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
    <mesh_term>Isophane Insulin, Human</mesh_term>
    <mesh_term>Insulin, Isophane</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>One patient was randomized but discontinued prior to treatment and is not included in any of the analyses. In the Participant Flow table, the term study outcome is used to differentiate it from serious adverse events (SAEs). By definition, the study outcomes were all SAEs as it was a cardiovascular outcome trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Postprandial</title>
          <description>Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
        </group>
        <group group_id="P2">
          <title>Fasting</title>
          <description>Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="558"/>
                <participants group_id="P2" count="558"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="338"/>
                <participants group_id="P2" count="346"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="220"/>
                <participants group_id="P2" count="212"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient moved</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol entry criteria not met</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Severity of outcome</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor's decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Postprandial</title>
          <description>Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
        </group>
        <group group_id="B2">
          <title>Fasting</title>
          <description>Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="557"/>
            <count group_id="B2" value="558"/>
            <count group_id="B3" value="1115"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.1" spread="9.7"/>
                    <measurement group_id="B2" value="60.9" spread="9.8"/>
                    <measurement group_id="B3" value="61.0" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="201"/>
                    <measurement group_id="B2" value="208"/>
                    <measurement group_id="B3" value="409"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="356"/>
                    <measurement group_id="B2" value="350"/>
                    <measurement group_id="B3" value="706"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Slovakia (Slovak Republic)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lebanon</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Turkey</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Croatia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="484"/>
                    <measurement group_id="B2" value="483"/>
                    <measurement group_id="B3" value="967"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Western Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African Descent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experienced a Primary Combined Outcome</title>
        <description>The combined study outcomes consisted of cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, hospitalization for acute coronary syndromes (HACS), and coronary revascularization procedures planned after randomization.</description>
        <time_frame>Randomization (Day 0) until first occurrence of primary combined outcome (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)</time_frame>
        <population>All randomized patients who took at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Postprandial</title>
            <description>Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
          <group group_id="O2">
            <title>Fasting</title>
            <description>Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced a Primary Combined Outcome</title>
          <description>The combined study outcomes consisted of cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, hospitalization for acute coronary syndromes (HACS), and coronary revascularization procedures planned after randomization.</description>
          <population>All randomized patients who took at least one dose of study drug</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="557"/>
                <count group_id="O2" value="558"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174"/>
                    <measurement group_id="O2" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To achieve 80% power, 490 pts need to experience primary combined CV outcome to detect diff. between treatments, assuming: &gt;=18.5% reduction in incidence of outcomes, 18 mo. pt recruitment, 18 mo. pt follow-up, 10% annual drop-out rate, 2-yr outcome incidence rate of &gt;=40% (pts in least efficacious treatment), and nominal 2-sided signif. of 0.045.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.866</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Death From Any Cause or Any One of the Primary Outcomes</title>
        <description>Primary outcomes in this study consisted of: cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for acute coronary syndromes (HACS), and coronary revascularization procedure planned after randomization.</description>
        <time_frame>Randomization (Day 0) until death from any cause or one of the primary outcomes (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)</time_frame>
        <population>All randomized patients who took at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Postprandial</title>
            <description>Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
          <group group_id="O2">
            <title>Fasting</title>
            <description>Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Death From Any Cause or Any One of the Primary Outcomes</title>
          <description>Primary outcomes in this study consisted of: cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for acute coronary syndromes (HACS), and coronary revascularization procedure planned after randomization.</description>
          <population>All randomized patients who took at least one dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="557"/>
                <count group_id="O2" value="558"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178"/>
                    <measurement group_id="O2" value="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.715</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Any One of the Primary Outcomes Adjusted for Indicators of Metabolic Control</title>
        <description>Indicators of metabolic control included glycosylated hemoglobin (HbA1c) and fasting blood glucose concentrations.</description>
        <time_frame>Randomization (Day 0) until occurrence of primary outcome (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)</time_frame>
        <population>All randomized patients who took at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Postprandial</title>
            <description>Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
          <group group_id="O2">
            <title>Fasting</title>
            <description>Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Any One of the Primary Outcomes Adjusted for Indicators of Metabolic Control</title>
          <description>Indicators of metabolic control included glycosylated hemoglobin (HbA1c) and fasting blood glucose concentrations.</description>
          <population>All randomized patients who took at least one dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="557"/>
                <count group_id="O2" value="558"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174"/>
                    <measurement group_id="O2" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.914</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Primary Outcomes Adjusted for Metabolic Control and Major Cardiovascular (CV) Risk Factors</title>
        <description>Primary outcomes adjusted for major cardiovascular (CV) risk factors (blood pressure, cholesterol [total, high density lipoprotein (HDL), and low density lipoprotein (LDL)], triglycerides, smoking, albuminuria, age, gender, and body mass index (BMI).</description>
        <time_frame>Randomization (Day 0) until occurrence of primary outcome (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)</time_frame>
        <population>All randomized patients who took at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Postprandial</title>
            <description>Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
          <group group_id="O2">
            <title>Fasting</title>
            <description>Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Primary Outcomes Adjusted for Metabolic Control and Major Cardiovascular (CV) Risk Factors</title>
          <description>Primary outcomes adjusted for major cardiovascular (CV) risk factors (blood pressure, cholesterol [total, high density lipoprotein (HDL), and low density lipoprotein (LDL)], triglycerides, smoking, albuminuria, age, gender, and body mass index (BMI).</description>
          <population>All randomized patients who took at least one dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="557"/>
                <count group_id="O2" value="558"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174"/>
                    <measurement group_id="O2" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.706</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Death From Any Cause</title>
        <time_frame>Randomization (Day 0) until death from any cause (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)</time_frame>
        <population>All randomized patients who took at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Postprandial</title>
            <description>Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
          <group group_id="O2">
            <title>Fasting</title>
            <description>Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Death From Any Cause</title>
          <population>All randomized patients who took at least one dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="557"/>
                <count group_id="O2" value="558"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.982</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Cardiovascular (CV) Death</title>
        <time_frame>Randomization (Day 0) until cardiovascular death (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)</time_frame>
        <population>All randomized patients who took at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Postprandial</title>
            <description>Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
          <group group_id="O2">
            <title>Fasting</title>
            <description>Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Cardiovascular (CV) Death</title>
          <population>All randomized patients who took at least one dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="557"/>
                <count group_id="O2" value="558"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.816</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Myocardial Infarction (MI)</title>
        <description>Occurrence of myocardial infarction (MI) (fatal, nonfatal, any).</description>
        <time_frame>Randomization (Day 0) until myocardial infarction (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)</time_frame>
        <population>All randomized patients who took at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Postprandial</title>
            <description>Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
          <group group_id="O2">
            <title>Fasting</title>
            <description>Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Myocardial Infarction (MI)</title>
          <description>Occurrence of myocardial infarction (MI) (fatal, nonfatal, any).</description>
          <population>All randomized patients who took at least one dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="557"/>
                <count group_id="O2" value="558"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.948</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Stroke</title>
        <description>Occurrence of stroke (fatal, nonfatal, any).</description>
        <time_frame>Randomization (Day 0) until stroke (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)</time_frame>
        <population>All randomized patients who took at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Postprandial</title>
            <description>Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
          <group group_id="O2">
            <title>Fasting</title>
            <description>Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Stroke</title>
          <description>Occurrence of stroke (fatal, nonfatal, any).</description>
          <population>All randomized patients who took at least one dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="557"/>
                <count group_id="O2" value="558"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.581</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.20</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Hospitalization for Acute Coronary Syndromes (HACS)</title>
        <time_frame>Randomization (Day 0) until HACS (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)</time_frame>
        <population>All randomized patients who took at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Postprandial</title>
            <description>Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
          <group group_id="O2">
            <title>Fasting</title>
            <description>Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Hospitalization for Acute Coronary Syndromes (HACS)</title>
          <population>All randomized patients who took at least one dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="557"/>
                <count group_id="O2" value="558"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.647</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Coronary Revascularization Procedures</title>
        <description>Occurrence of all coronary revascularization procedures (angioplasty or coronary artery by-pass surgery) planned after randomization.</description>
        <time_frame>Randomization (Day 0) until coronary revascularization procedures (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)</time_frame>
        <population>All randomized patients who took at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Postprandial</title>
            <description>Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
          <group group_id="O2">
            <title>Fasting</title>
            <description>Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Coronary Revascularization Procedures</title>
          <description>Occurrence of all coronary revascularization procedures (angioplasty or coronary artery by-pass surgery) planned after randomization.</description>
          <population>All randomized patients who took at least one dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="557"/>
                <count group_id="O2" value="558"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.525</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Amputation for Peripheral Vascular Disease Planned After Randomization</title>
        <time_frame>Randomization (Day 0) until amputation (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)</time_frame>
        <population>All randomized patients who took at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Postprandial</title>
            <description>Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
          <group group_id="O2">
            <title>Fasting</title>
            <description>Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Amputation for Peripheral Vascular Disease Planned After Randomization</title>
          <population>All randomized patients who took at least one dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="557"/>
                <count group_id="O2" value="558"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.800</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Congestive Heart Failure</title>
        <description>Occurrence of congestive heart failure (newly diagnosed after Visit 2).</description>
        <time_frame>Randomization (Day 0) until congestive heart failure (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)</time_frame>
        <population>All randomized patients who took at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Postprandial</title>
            <description>Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
          <group group_id="O2">
            <title>Fasting</title>
            <description>Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Congestive Heart Failure</title>
          <description>Occurrence of congestive heart failure (newly diagnosed after Visit 2).</description>
          <population>All randomized patients who took at least one dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="557"/>
                <count group_id="O2" value="558"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.662</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Revascularization Procedure for Peripheral Vascular Disease Planned After Randomization</title>
        <time_frame>Randomization (Day 0) until revascularization procedure (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)</time_frame>
        <population>All randomized patients who took at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Postprandial</title>
            <description>Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
          <group group_id="O2">
            <title>Fasting</title>
            <description>Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Revascularization Procedure for Peripheral Vascular Disease Planned After Randomization</title>
          <population>All randomized patients who took at least one dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="557"/>
                <count group_id="O2" value="558"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.863</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Coronary Angiography Planned After Randomization</title>
        <time_frame>Randomization (Day 0) until coronary angiography (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)</time_frame>
        <population>All randomized patients who took at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Postprandial</title>
            <description>Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
          <group group_id="O2">
            <title>Fasting</title>
            <description>Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Coronary Angiography Planned After Randomization</title>
          <population>All randomized patients who took at least one dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="557"/>
                <count group_id="O2" value="558"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.471</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Self-Reported Hypoglycemia During Month 1</title>
        <description>Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).</description>
        <time_frame>Visit 3 (Month 1)</time_frame>
        <population>All randomized patients who took at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Postprandial</title>
            <description>Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
          <group group_id="O2">
            <title>Fasting</title>
            <description>Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Self-Reported Hypoglycemia During Month 1</title>
          <description>Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).</description>
          <population>All randomized patients who took at least one dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="557"/>
                <count group_id="O2" value="557"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7168</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 1</title>
        <description>Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).</description>
        <time_frame>Visit 3 (Month 1)</time_frame>
        <population>All randomized participants who self-reported hypoglycemia during Month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Postprandial</title>
            <description>Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
          <group group_id="O2">
            <title>Fasting</title>
            <description>Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 1</title>
          <description>Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).</description>
          <population>All randomized participants who self-reported hypoglycemia during Month 1.</population>
          <units>episodes of hypoglycemia</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="353"/>
                    <measurement group_id="O2" value="302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Self-Reported Hypoglycemia During Month 3</title>
        <description>Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).</description>
        <time_frame>Visit 4 (Month 3)</time_frame>
        <population>All randomized patients who took at least one dose of study drug and who were still in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Postprandial</title>
            <description>Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
          <group group_id="O2">
            <title>Fasting</title>
            <description>Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Self-Reported Hypoglycemia During Month 3</title>
          <description>Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).</description>
          <population>All randomized patients who took at least one dose of study drug and who were still in the study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="511"/>
                <count group_id="O2" value="525"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160"/>
                    <measurement group_id="O2" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0860</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 3</title>
        <description>Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).</description>
        <time_frame>Visit 4 (Month 3)</time_frame>
        <population>All randomized participants who self-reported hypoglycemia during Month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Postprandial</title>
            <description>Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
          <group group_id="O2">
            <title>Fasting</title>
            <description>Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 3</title>
          <description>Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).</description>
          <population>All randomized participants who self-reported hypoglycemia during Month 3.</population>
          <units>episodes of hypoglycemia</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="567"/>
                    <measurement group_id="O2" value="524"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Self-Reported Hypoglycemia During Month 6</title>
        <description>Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).</description>
        <time_frame>Visit 5 (Month 6)</time_frame>
        <population>All randomized patients who took at least one dose of study drug and who were still in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Postprandial</title>
            <description>Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
          <group group_id="O2">
            <title>Fasting</title>
            <description>Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Self-Reported Hypoglycemia During Month 6</title>
          <description>Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).</description>
          <population>All randomized patients who took at least one dose of study drug and who were still in the study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="493"/>
                <count group_id="O2" value="504"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163"/>
                    <measurement group_id="O2" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1424</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Summary of Reasons for Deaths</title>
        <time_frame>Randomization (Day 0) to death (18 month initial treatment period, extended treatment follow-up period up to 5.5 years)</time_frame>
        <population>All randomized patients who took at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Postprandial</title>
            <description>Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
          <group group_id="O2">
            <title>Fasting</title>
            <description>Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Reasons for Deaths</title>
          <population>All randomized patients who took at least one dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="557"/>
                <count group_id="O2" value="558"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fatal MI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal Stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CV Death other than Stroke/MI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-CV Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 6</title>
        <description>Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).</description>
        <time_frame>Visit 5 (Month 6)</time_frame>
        <population>All randomized participants with self-reported hypoglycemia during Month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Postprandial</title>
            <description>Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
          <group group_id="O2">
            <title>Fasting</title>
            <description>Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 6</title>
          <description>Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).</description>
          <population>All randomized participants with self-reported hypoglycemia during Month 6.</population>
          <units>episodes of hypoglycemia</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="770"/>
                    <measurement group_id="O2" value="576"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Self-Reported Hypoglycemia During Month 9</title>
        <description>Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).</description>
        <time_frame>Visit 6 (Month 9)</time_frame>
        <population>All randomized patients who took at least one dose of study drug and who were still in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Postprandial</title>
            <description>Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
          <group group_id="O2">
            <title>Fasting</title>
            <description>Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Self-Reported Hypoglycemia During Month 9</title>
          <description>Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).</description>
          <population>All randomized patients who took at least one dose of study drug and who were still in the study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="483"/>
                <count group_id="O2" value="488"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155"/>
                    <measurement group_id="O2" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1957</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 9</title>
        <description>Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).</description>
        <time_frame>Visit 6 (Month 9)</time_frame>
        <population>All randomized participants with self-reported hypoglycemia during Month 9.</population>
        <group_list>
          <group group_id="O1">
            <title>Postprandial</title>
            <description>Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
          <group group_id="O2">
            <title>Fasting</title>
            <description>Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 9</title>
          <description>Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).</description>
          <population>All randomized participants with self-reported hypoglycemia during Month 9.</population>
          <units>episodes of hypoglycemia</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of Episodes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="747"/>
                    <measurement group_id="O2" value="569"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Self-Reported Hypoglycemia During Month 12</title>
        <description>Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).</description>
        <time_frame>Visit 7 (Month 12)</time_frame>
        <population>All randomized patients who took at least one dose of study drug and who were still in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Postprandial</title>
            <description>Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
          <group group_id="O2">
            <title>Fasting</title>
            <description>Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Self-Reported Hypoglycemia During Month 12</title>
          <description>Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).</description>
          <population>All randomized patients who took at least one dose of study drug and who were still in the study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="470"/>
                <count group_id="O2" value="471"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2434</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 12</title>
        <description>Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).</description>
        <time_frame>Visit 7 (Month 12)</time_frame>
        <population>All randomized participants with self-reported hypoglycemia during Month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Postprandial</title>
            <description>Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
          <group group_id="O2">
            <title>Fasting</title>
            <description>Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 12</title>
          <description>Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).</description>
          <population>All randomized participants with self-reported hypoglycemia during Month 12.</population>
          <units>episodes of hypoglycemia</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="710"/>
                    <measurement group_id="O2" value="486"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Self-Reported Hypoglycemia During Month 18</title>
        <description>Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).</description>
        <time_frame>Visit 8 (Month 18)</time_frame>
        <population>All randomized patients who took at least one dose of study drug and who were still in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Postprandial</title>
            <description>Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
          <group group_id="O2">
            <title>Fasting</title>
            <description>Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Self-Reported Hypoglycemia During Month 18</title>
          <description>Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).</description>
          <population>All randomized patients who took at least one dose of study drug and who were still in the study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="452"/>
                <count group_id="O2" value="457"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                    <measurement group_id="O2" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2617</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 18</title>
        <description>Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).</description>
        <time_frame>Visit 8 (Month 18)</time_frame>
        <population>All randomized participants with self-reported hypoglycemia during Month 18.</population>
        <group_list>
          <group group_id="O1">
            <title>Postprandial</title>
            <description>Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
          <group group_id="O2">
            <title>Fasting</title>
            <description>Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 18</title>
          <description>Hypoglycemia was defined as any time a patient feels, or another person observes, that the patient is experiencing a sign/symptom which he/she would associate with hypoglycemia (for example, tremors, headache, sweating, disorientation, weakness, etc) or a blood glucose measurement less than 3.5 mmol/L (63 mg/dL).</description>
          <population>All randomized participants with self-reported hypoglycemia during Month 18.</population>
          <units>episodes of hypoglycemia</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="945"/>
                    <measurement group_id="O2" value="669"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Postprandial</title>
          <description>Insulin lispro: Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study; Human insulin isophane suspension: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
        </group>
        <group group_id="E2">
          <title>Fasting</title>
          <description>Human insulin isophane suspension: injected subcutaneous (SC) twice daily before the morning and evening meals until patient completes study; Insulin glargine: injected subcutaneous (SC) once daily in the evening until patient completes study; or Human insulin 30/70: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values &gt;8.0%.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="145"/>
                <counts group_id="E2" subjects_affected="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Hypochromic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="557"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="557"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Conduction disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Coronary artery restenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Dressler's syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Ventricular tachyarrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="557"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Gastrointestinal telangiectasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Mouth cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="557"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Hernia obstructive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="557"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="557"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Chronic tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Mediastinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Perianal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="557"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Purulent pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Pyometra</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Septic arthritis staphylococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="557"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Wound sepsis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Glaucoma traumatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Traumatic intracranial haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="557"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Insulin resistance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma pancreas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Bile duct cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Choroid melanoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma stage II</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma stage unspecified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Carotid artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Cluster headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Hypotonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Intercostal neuralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Mononeuropathy multiplex</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Psychomotor hyperactivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood disorder due to a general medical condition</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Post-traumatic stress disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Psychotic disorder due to a general medical condition</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Urethral obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Polycystic ovaries</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Pharyngeal oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="557"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Vocal cord polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Idiopathic urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Photodermatosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Implantable defibrillator insertion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Toe amputation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Accelerated hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Arterial stenosis limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis obliterans</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Post thrombotic syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="356"/>
                <counts group_id="E2" subjects_affected="346"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="557"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="557"/>
                <counts group_id="E2" events="29" subjects_affected="29" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="557"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="557"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="557"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="557"/>
                <counts group_id="E2" events="29" subjects_affected="29" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="35" subjects_affected="35" subjects_at_risk="557"/>
                <counts group_id="E2" events="36" subjects_affected="36" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="557"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Arteriogram coronary</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="557"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="557"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="557"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="557"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="557"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="557"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="557"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="558"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="557"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="557"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="557"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="557"/>
                <counts group_id="E2" events="27" subjects_affected="27" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>1-800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

